Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
Description:
The purpose of this study is to demonstrate whether finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality in subjects with Type 2 Diabetes Mellitus and clinical diagnosis of diabetic kidney disease.
This study involves:
- Taking the study drug finerenone or inactive medication (placebo).
- 16 study visits in a span of 2 years. After the first month the visits will be every 4 months.
- Duration of study will be approximately 2 years.
Monetary compensation and parking validation will be provided for eligible study participants.
Recruitment:
- Men or women 18 years or older
- Type 2 Diabetes Mellitus (T2DM)
- Clinical diagnosis of Diabetic Kidney Disease
- Receiving treatment for high blood pressure
Contact:
Taylor Pierce at 617-309-4616 or taylor.pierce [at] joslin.harvard.edu ()
CHS(#2016-15)